
Thursday, June 05, 2025 7:33:58 AM
Putting intentionally false information in an SEC filing is not “perjury”.
Go educate yourself as to what “perjury” actually is.
Sheesh.
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, the CEO and CFO of a public company must certify in the Form 10-K (and Form 10-Q) that the information in the report is accurate and does not contain material misstatements or omissions, to the best of their knowledge. These certifications are made under penalty of perjury, as outlined in 18 U.S.C. § 1350, which imposes criminal penalties for false certifications, including potential fines and imprisonment.
Now, will he spend allday arguing with others about how wrong this is and how right he is...probably!
Furthermore...
OMOLIVES
Re: None
Wednesday, 06/04/2025 9:49:45 PM
Sure must be one hell of a Quarterly filing. Just remember that if the chance comes , take advantage quick. This thing is so fn' done. No gas left and too much damage. Good luck.
Have you reviewed the recently approved SMX proxy statement? It's eye-opening! With just a bit of critical thinking and forward thought, I can highlight two compelling reasons why you might want to hold off on selling your HMBL shares. I'll see if you can figure it out on your own 😁
Recent HMBL News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 07/09/2025 03:00:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/05/2025 09:30:06 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/09/2025 09:31:33 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 04/30/2025 08:47:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/18/2025 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2025 08:34:05 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2025 03:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/18/2025 08:10:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2025 10:13:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 10:27:27 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 12/26/2024 09:05:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 07:25:49 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/20/2024 02:43:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 09:05:16 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 12/11/2024 10:21:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2024 03:42:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/19/2024 09:00:38 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2024 11:14:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 04:10:18 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 09/11/2024 08:35:17 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 08/30/2024 08:40:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:53:54 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 08:16:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:05:13 PM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM